Abstract
Leptin is a small peptide hormone (16 kDa), a product of the obesity gene (Ob), and is mainly synthesized and secreted by adipocytes. It is removed from the blood by the kidneys. The kidney is not only a site of leptin clearance, but also a target organ for its action in different pathophysiological states. Several studies have documented a strong relationship between chronic kidney disease (CKD) and accelerated cardiovascular disease (CVD) defined as a cardiorenal syndrome. Patients with stage 3 and 4 CKD develop cardiovascular complications and are at increased risk of death from CVD. Renal dysfunction promotes several mechanisms responsible for exacerbation of cardiovascular disease. These include activation of the renin-angiotensin system, oxidative stress, elevated asymmetric dimethylarginine (ADMA), low-grade inflammation with increased circulating cytokines, and dyslipidemia. Recently, it has been observed that plasma leptin level is elevated in patients with cardiorenal syndrome. In obesity, hyperleptinemia combined with selective leptin resistance appear to have a critical role in the development and progression of kidney disease, CVD and metabolic syndrome. This has clinical implications for the treatment of obesity–related hypertension and kidney disease. In this paper the role of leptin in chronic kidney disease and accelerated cardiovascular disease is out lined. The link between hyperleptinemia and development and progression of morphologic changes that effect kidney in obese patients is also discussed.
Keywords: Leptin, cardiovascular disease, chronic kidney disease, obesity.
Current Pharmaceutical Design
Title:Increased Risk of Cardiovascular Complications in Chronic Kidney Disease: A Possible Role of Leptin
Volume: 20 Issue: 4
Author(s): Agnieszka Korolczuk and Jaroslaw Dudka
Affiliation:
Keywords: Leptin, cardiovascular disease, chronic kidney disease, obesity.
Abstract: Leptin is a small peptide hormone (16 kDa), a product of the obesity gene (Ob), and is mainly synthesized and secreted by adipocytes. It is removed from the blood by the kidneys. The kidney is not only a site of leptin clearance, but also a target organ for its action in different pathophysiological states. Several studies have documented a strong relationship between chronic kidney disease (CKD) and accelerated cardiovascular disease (CVD) defined as a cardiorenal syndrome. Patients with stage 3 and 4 CKD develop cardiovascular complications and are at increased risk of death from CVD. Renal dysfunction promotes several mechanisms responsible for exacerbation of cardiovascular disease. These include activation of the renin-angiotensin system, oxidative stress, elevated asymmetric dimethylarginine (ADMA), low-grade inflammation with increased circulating cytokines, and dyslipidemia. Recently, it has been observed that plasma leptin level is elevated in patients with cardiorenal syndrome. In obesity, hyperleptinemia combined with selective leptin resistance appear to have a critical role in the development and progression of kidney disease, CVD and metabolic syndrome. This has clinical implications for the treatment of obesity–related hypertension and kidney disease. In this paper the role of leptin in chronic kidney disease and accelerated cardiovascular disease is out lined. The link between hyperleptinemia and development and progression of morphologic changes that effect kidney in obese patients is also discussed.
Export Options
About this article
Cite this article as:
Korolczuk Agnieszka and Dudka Jaroslaw, Increased Risk of Cardiovascular Complications in Chronic Kidney Disease: A Possible Role of Leptin, Current Pharmaceutical Design 2014; 20 (4) . https://dx.doi.org/10.2174/13816128113199990013
DOI https://dx.doi.org/10.2174/13816128113199990013 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Diagnosis of Cardiovascular Diseases Using Retinal Images Through Vessel Segmentation Graph
Current Medical Imaging Pentraxins and Atherosclerosis: The Role of PTX3
Current Pharmaceutical Design S-Nitrosylation: Targets, Controls and Outcomes
Current Genomics Physico-Chemical Changes and Stability of Nutraceutical in Rice Bran Oil During Simulated Domestic Frying
Current Nutrition & Food Science Cell Cycle Dependent Regulation of Intracellular Calcium Concentration in Vascular Smooth Muscle Cells: A Potential Target for Drug Therapy
Current Drug Targets - Cardiovascular & Hematological Disorders Monitoring Cardiac Function During Idebenone Therapy in Friedreich's Ataxia
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Medical Imaging Steroid Hybrid Systems: New Molecular Entities with Potential Therapeutical Spectrum
Current Drug Therapy Myocardial Structure and Matrix Metalloproteinases
Current Topics in Medicinal Chemistry Relevance of Endothelial-Haemostatic Dysfunction in Cigarette Smoking
Current Medicinal Chemistry A<sub>3</sub> Adenosine Receptor: A Plausible Therapeutic Target for Cardio-Protection in Diabetes
Recent Patents on Cardiovascular Drug Discovery Anti-Inflammatory Therapy in Uveitis
Recent Patents on Inflammation & Allergy Drug Discovery Perinatal Heart Programming: Long-term Consequences
Current Medicinal Chemistry Editorial (Hot Topic :Advances in Industry for Chronic Respiratory Diseases)
Inflammation & Allergy - Drug Targets (Discontinued) Antisense Oligonucleotides for the Treatment of Dyslipidemia
Current Pharmaceutical Design Novel Therapeutic Targets for Phosphodiesterase 5 Inhibitors: current state-of-the-art on systemic arterial hypertension and atherosclerosis
Current Pharmaceutical Biotechnology Diet Effects on Atherosclerosis in Mice
Current Drug Targets The Relation Between the Chemical Structure of Flavonoids and Their Estrogen-Like Activities
Current Medicinal Chemistry Recent Patents in siRNA Delivery Employing Nanoparticles as Delivery Vectors
Recent Patents on DNA & Gene Sequences Curcumin: the Yellow Molecule with Pleiotropic Biological Effects
Letters in Drug Design & Discovery